Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 120993-53-5
Drug Levels and Effects
Summary of Use during Lactation
Desirudin is no longer marketed in the United States. Because no information is available on the use of desirudin during breastfeeding, an alternate drug is preferred.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
Acenocoumarol, Dalteparin, Enoxaparin, Heparin, Rivaroxaban, Warfarin
Substance Identification
Substance Name
Desirudin
CAS Registry Number
120993-53-5
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- Review Lepirudin.[Drugs and Lactation Database (...]Review Lepirudin.. Drugs and Lactation Database (LactMed®). 2006
- Review Desirudin: a review of the pharmacology and clinical application for the prevention of deep vein thrombosis.[Expert Rev Cardiovasc Ther. 2011]Review Desirudin: a review of the pharmacology and clinical application for the prevention of deep vein thrombosis.Graetz TJ, Tellor BR, Smith JR, Avidan MS. Expert Rev Cardiovasc Ther. 2011 Sep; 9(9):1101-9.
- Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement.[J Bone Joint Surg Am. 1997]Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement.Eriksson BI, Ekman S, Lindbratt S, Baur M, Bach D, Torholm C, Kälebo P, Close P. J Bone Joint Surg Am. 1997 Mar; 79(3):326-33.
- A recombinant hirudin (IK-HIR02) in healthy volunteers. I. Effects on coagulation parameters and bleeding time.[Haemostasis. 1996]A recombinant hirudin (IK-HIR02) in healthy volunteers. I. Effects on coagulation parameters and bleeding time.Schenk JF, Glusa E, Radziwon P, Butti A, Markwardt F, Breddin HK. Haemostasis. 1996 May-Jun; 26(3):140-9.
- Molecular dynamic and pharmacological studies on protein-engineered hirudin variants of Hirudinaria manillensis and Hirudo medicinalis.[Br J Pharmacol. 2022]Molecular dynamic and pharmacological studies on protein-engineered hirudin variants of Hirudinaria manillensis and Hirudo medicinalis.Sun Y, Wang B, Pei J, Luo Y, Yuan N, Xiao Z, Wu H, Luo C, Wang J, Wei S, et al. Br J Pharmacol. 2022 Jul; 179(14):3740-3753. Epub 2022 Mar 15.
- Desirudin - Drugs and Lactation Database (LactMed®)Desirudin - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...